DR info

臨床試験数 : 16 / 薬物数 : 28 - (DrugBank : 13) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 38

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

18F-AV-1451
   Skåne University Hospital, Region Skåne
      2014   -   EUCTR2014-000422-38-SE   Sweden;
18F-FDG
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan;
18F-RO6958948
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
ABBV-8E12
   AbbVie
      2018   -   NCT03744546   -
Anti-Parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Apomorphine
   Fondation Ophtalmologique Adolphe de Rothschild
      2018   -   NCT04786158   France;
BIIB092
   University of California, San Francisco
      2018   Phase 1   NCT03658135   United States;
Brain PET scan
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States;
Davunetide (AL-108, NAP)
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States;
Deep Brain Stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Dopamine
   Juntendo University school of MedicineDepartment of Diagnosis, Prevention and Treatment of Dementia
      2014   -   JPRN-UMIN000014098   Japan;
Fasudil
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT04734379   United States;
Flortaucipir F18
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States;
Flutemetamol
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   Japan;
Flutemetamol F18
   Skane University Hospital
      2017   -   NCT03174938   Sweden;
Leucine
   Washington University School of Medicine
      2017   -   NCT03545126   United States;
Lithium
   Westat
      2008   Phase 1/Phase 2   NCT00703677   United Kingdom;United States;
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Raclopride
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan;
TPI 287 2 mg/m2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPI-287 20 mg/m2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPI-287 6.3 mg/m2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
Vizamyl (flutemetamol(F-18))
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;